21 43 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Gilead, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

February 19, 2013 | BioWorld
Bispecific Antibodies Capturing Great Deal of Industry Interest

January 07, 2013 | Washington Business Journal
MacroGenics Could Get $1B Payday

January 07, 2013 | Dow Jones Business News
MacroGenics Strikes Another Deal; Gilead Alliance Could Yield More Than $1 Billion

January 07, 2013 | BioCentury Extra
MacroGenics, Gilead in mAb DART Deal

January 07, 2013 | Fierce Biotech
Gilead and Biotech Strike Antibody Deal Worth North of $1.1B--Maybe

January 07, 2013 | BioWorld
MacroGenics DART Platform Grabs Potential $1B Gilead Deal

November 19, 2012 | The Pink Sheet
How to Place Bets on Early Oncology Assets

October 01, 2012 | Drug Discovery News
A Picture Perfect Focus

September 27, 2012 | Fierce Biotech
10 Next-gen Biologics Platforms to Watch

September 21, 2012 | "The Pink Sheet" Daily
MacroGenics Strikes Second Oncology Partnership with Servier

News Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All